Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Department of Gastroenterology, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China.
Clin Chim Acta. 2018 Apr;479:43-47. doi: 10.1016/j.cca.2018.01.005. Epub 2018 Jan 5.
It has been reported that lncRNA X-inactive specific transcript (XIST) is dysregulated in various cancers. We performed this meta-analysis to clarify its promising functions as a prognosis marker in malignant tumors.
Eligible studies were recruited by a systematic search in OVID, Embase, Web of Science and PubMed databases. The hazard ratio (HR) and 95% confidence interval (CI) were calculated to explore the relationship between lncRNA XIST expression and patient's survival, which were extracted from the eligible studies. The odds ratio (OR) was calculated to assess the association between lncRNA XIST expression and pathological parameters using stata12.0 software.
Total 10 studies and 878 cancer patients were included in the study. The pooled HR suggested that high lncRNA XIST expression was significantly correlated with poor overall survival (OS) (HR=2.61, 95% CI=1.91-3.13, P<0.0001) and short disease-free survival (DFS) (HR=2.10, 95% CI=1.10-3.11, P<0.0001). It was demonstrated high level of lncRNA XIST was positively correlated with larger tumor size (OR=1.89, 95% CI 1.34-2.06, P<0.001), positive distant metastasis (OR=1.75, 95% CI 1.03-2.96, P=0.038) and high-grade cancer (OR=1.64, 95% CI 1.22-2.21, P<0.001). However, no correlation was observed between expression of lncRNA XIST and age (OR=0.86, 95% CI 0.62-1.19, P=0.352), gender (OR=0.98, 95% CI 0.73-1.33, P=0.769), lymphatic metastasis (OR=1.41, 95% CI 0.97-2.04, P=0.069) and differentiation (OR=1.16, 95% CI 0.76-1.77, P=0.497).
This meta-analysis demonstrated that elevated lncRNA XIST expression predicts poor OS, poor DFS, larger tumor size, increased distant metastasis and advanced tumor stage, suggesting that high lncRNA XIST expression may serve as a novel biomarker for poor prognosis and metastasis in cancers.
已有研究报道长链非编码 RNA X 失活特异性转录物（lncRNA XIST）在多种癌症中失调。我们进行了这项荟萃分析，以明确其作为恶性肿瘤预后标志物的潜在功能。
通过在 OVID、Embase、Web of Science 和 PubMed 数据库中进行系统搜索，招募了符合条件的研究。从合格的研究中提取风险比（HR）和 95%置信区间（CI）来探讨 lncRNA XIST 表达与患者生存之间的关系。使用 stata12.0 软件计算比值比（OR）来评估 lncRNA XIST 表达与病理参数之间的关联。
共纳入 10 项研究和 878 例癌症患者。合并 HR 表明，lncRNA XIST 高表达与总生存期（OS）（HR=2.61，95%CI=1.91-3.13，P<0.0001）和无病生存期（DFS）（HR=2.10，95%CI=1.10-3.11，P<0.0001）较短显著相关。结果表明，lncRNA XIST 水平较高与肿瘤较大（OR=1.89，95%CI 1.34-2.06，P<0.001）、远处转移阳性（OR=1.75，95%CI 1.03-2.96，P=0.038）和高级别癌症（OR=1.64，95%CI 1.22-2.21，P<0.001）呈正相关。然而，lncRNA XIST 的表达与年龄（OR=0.86，95%CI 0.62-1.19，P=0.352）、性别（OR=0.98，95%CI 0.73-1.33，P=0.769）、淋巴转移（OR=1.41，95%CI 0.97-2.04，P=0.069）和分化（OR=1.16，95%CI 0.76-1.77，P=0.497）无相关性。
这项荟萃分析表明，升高的 lncRNA XIST 表达预示着 OS 不良、DFS 不良、肿瘤较大、远处转移增加和肿瘤分期较高，提示高 lncRNA XIST 表达可能成为癌症不良预后和转移的新型生物标志物。
